Susan Drapeau

Susan Drapeau


Susan Drapeau is the Vice President for Product Development and commercialisation at Bruder Consulting and Venture Group (BCVG). Susan has over 24 years of industry experience in cell therapy, biologics, biomaterials, protein therapies and medical device development. Before joining BCVG in 2022, Susan led product development, regulatory, preclinical, and programme management at Sigilon Therapeutics, a cell therapy company combining biomaterials and cellular engineering to treat rare diseases.

Susan Drapeau is the Vice President for Product Development and commercialisation at Bruder Consulting and Venture Group (BCVG). Susan has over 24 years of industry experience in cell therapy, biologics, biomaterials, protein therapies and medical device development. Before joining BCVG in 2022, Susan led product development, regulatory, preclinical, and programme management at Sigilon Therapeutics, a cell therapy company combining biomaterials and cellular engineering to treat rare diseases. Previously, she served as the Senior Director of Business Development and Strategy at Vericel Corporation. Before that, she spent 14 years at Medtronic Spine, running part of the Biologics product development organisation and leading due diligence efforts. While at Medtronic, her team launched numerous products, submitted INDs, supported manufacturing and more. Earlier in her career, she worked at Osiris Therapeutics, leading allogeneic cell therapies in orthopaedics. Susan advocates for the biomedical field as part of AIMBE and sits on the Advisory Board for the Department of Biomedical Engineering at Rice University. Susan is a graduate of Purdue University (BS, Chemical Engineering and BS, Chemistry) and Rice University (PhD, Chemical Engineering).